Fig. 1 · Structure

Documents & Downloads

Iloperidone

Cat. No. A10467 CAS 133454-47-4
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Iloperidone shows functional antagonist activity at dopamine, serotonin and adrenergic receptors. In a HEK293T ONE-GO biosensor panel, it inhibited responses including D2, D3, 5-HT2A and α2C signaling, with generally low agonist efficacy. The assay also detected inverse agonism at 5-HT1B and 5-HT1D. These functional responses do not establish receptor-binding affinities or clinical efficacy. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
5-HT

Iloperidone Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Iloperidone from 2 published references.

Iloperidone In Vitro Studies

Iloperidone responses can vary with receptor sequence in a transfected-cell assay. The 5-HT1B F124C and R230H variants reduced inverse-agonist efficacy relative to wild type, whereas the tested 5-HT1A A50V and R220L variants did not change iloperidone effects. Possible receptor-expression differences were not resolved, and the results do not establish patient responses. [1]

Functional monoamine-receptor profiling with ONE-GO biosensors

Cell-based study · HEK293T cells expressing individual GPCRs and cognate ONE-GO G-protein biosensors; 45-receptor panel [1]

Iloperidone inhibited agonist-evoked signaling at dopamine, serotonin and adrenergic receptors, with generally poor agonist efficacy in this panel. The same profiling experiment detected inverse agonism at 5-HT1B and 5-HT1D. This is a functional G-protein readout, not a binding-affinity determination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Agonist-evoked G-protein activation across the receptor panelNormalized ΔBRET Qualitative antagonism including D2R, D3R, 5-HT2A and α2C-AR; mean, n=3–7 as reported for Figure 5A.[1]
Basal signaling at 5-HT1B and 5-HT1DNormalized ΔBRET Inverse-agonist responses with iloperidone; qualitative result, no exact potency estimated from the heatmap.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 nM, 10 nM, 100 nM, 1 µM and 10 µM, plus zero-drug condition (Figure 5A log[M] −9 to −5).
Exposure duration
Endpoint BRET was recorded every minute for 5 min; methods state that the analyzed time point depended on receptor/G-protein kinetics.
Method
Cell-based ONE-GO BRET assay; transient calcium-phosphate transfection.
Vehicle
Drug solvent not specified in the selected main-text BRET methods.
Co-treatment
Cognate receptor agonist at EC80 in antagonist mode; drug alone in agonist mode. Brexpiprazole and cariprazine were separate comparators, not combination treatments.
Reported limits
Receptor-specific agonist concentrations, biosensor assignments and underlying values in SI5 were not retrieved. No exact receptor-specific IC50, Ki or selected analysis minute is supplied.
Methods and source locations

Compound reported in the paper: Iloperidone; Compound label in the paper: Iloperidone

Results apply to the reported iloperidone reagent and assay systems; no supplier or lot equivalence is established.

Figure 5A and caption; Results: Parallel profiling of atypical antipsychotics; STAR Methods: HEK293T BRET measurements and Key Resources Table

Agonist-evoked G-protein activation across the receptor panel: Iloperidone alone or with a cognate agonist at EC80; ΔBRET normalized to the cognate EC80 response. — Figure 5A heatmap and caption; Parallel profiling results; BRET methods, Figure 5A normalization

Basal signaling at 5-HT1B and 5-HT1D: Drug-alone mode of the same panel; responses below the no-agonist baseline. — Figure 5A heatmap; Parallel profiling results

Serotonin-receptor variants modify selected functional responses

Cell-based study · HEK293T cells expressing wild-type or variant 5-HT1A/5-HT1B receptors and the Gαi1 ONE-GO biosensor [1]

The 5-HT1B F124C and R230H variants reduced iloperidone inverse-agonist efficacy relative to wild type. The tested 5-HT1A A50V and R220L variants did not change iloperidone effects in the authors’ analysis. This assay did not establish whether expression differences contributed to variant responses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Effects of receptor variants on iloperidone functional efficacyNormalized ΔBRET Reduced inverse-agonist efficacy at 5-HT1B F124C and R230H; no change in iloperidone effects at 5-HT1A A50V or R220L. Figure 5B: mean ± SEM, n=3–4.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Iloperidone concentration-response curves, Figure 5B log[M] −10 to −5, with a drug-free condition.
Exposure duration
Shared endpoint BRET method: recording every minute for 5 min; receptor-specific analyzed time point not specified in the adopted scope.
Method
Cell-based ONE-GO Gαi1 BRET assay.
Vehicle
Drug solvent not specified in the selected main-text methods.
Co-treatment
Parallel drug-alone and serotonin-challenged conditions; Figure 5B labels serotonin 300 nM for 5-HT1A and 30 nM for 5-HT1B.
Reported limits
SI6 preliminary screen data were not retrieved. Receptor abundance/surface expression was not resolved for these comparisons; no exact potency or clinical pharmacogenomic effect is claimed.
Methods and source locations

Compound reported in the paper: Iloperidone; Compound label in the paper: Iloperidone

Results apply to the reported iloperidone reagent and assay systems; no supplier or lot equivalence is established.

Figure 5B and caption; Results: Pharmacogenomics of atypical antipsychotics; shared HEK293T BRET methods and Key Resources Table

Effects of receptor variants on iloperidone functional efficacy: Wild-type versus variant Gαi1 BRET responses; drug alone and with serotonin; serotonin-alone responses shown as controls. — Figure 5B curves and caption; Pharmacogenomics results

Iloperidone In Vivo Studies

In fasted female Sprague-Dawley rats, single subcutaneous iloperidone doses of 1.0, 5.0 and 10.0 mg/kg increased plasma insulin and HOMA-IR 30 minutes after administration versus vehicle. Fasting glucose was not significantly changed, and the lower tested doses were not marked significant for insulin or HOMA-IR. These acute pre-challenge findings identify a metabolic effect in this model; they do not determine chronic or human metabolic risk. [2]

Acute fasting metabolic responses in female rats

Animal study · Adult female Sprague-Dawley rats (250–275 g), fasting measurements within the IGTT experimental design [2]

A single subcutaneous iloperidone dose increased fasting insulin and HOMA-IR at 1.0, 5.0 and 10.0 mg/kg, while fasting glucose was not significantly altered. These are acute pre-challenge findings; HOMA-IR is a surrogate index and does not itself quantify clamp insulin sensitivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fasting glucose at 30 min, before glucose challengemmol/L 4.6±0.2; 4.9±0.2; 4.6±0.2; 4.9±0.2; 5.1±0.2; 5.2±0.3 (mean ± SEM). Dose order: vehicle, 0.03, 0.5, 1.0, 5.0, 10.0 mg/kg.[2]
Fasting plasma insulin at 30 min, before glucose challengeµU/ml 21.6±3.6; 21.6±2.6; 28.2±5.0; 40.1±4.9*; 44.9±3.6*; 58.8±7.7* (mean ± SEM). Dose order: vehicle, 0.03, 0.5, 1.0, 5.0, 10.0 mg/kg. *p<0.05 versus vehicle (Table 1).[2]
Fasting HOMA-IR at 30 min, before glucose challengeHOMA-IR; reported units (µU·mmol)/(ml·L) 4.6±0.8; 4.7±0.5; 5.9±1.2; 8.8±1.2*; 10.2±0.8*; 13.8±2.2* (mean ± SEM). Dose order: vehicle, 0.03, 0.5, 1.0, 5.0, 10.0 mg/kg. *p<0.05 versus vehicle (Table 1).[2]

Conditions shared by the study groups

Route
Subcutaneous injection
Frequency
Single administration
Treatment course
Fasted 16±2 h; selected fasting outcomes measured 30 min after treatment and before glucose challenge.
Vehicle
50% polyethylene glycol 400, 40% distilled water, 10% ethanol; dosing volume 1 ml/kg.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Single-dose iloperidone versus vehicle
0.03, 0.5, 1.0, 5.0 or 10.0 mg/kg
Vehicle-treated rats; baseline IGTT used for matching and re-randomization; handlers blinded to treatment.Fasting insulin and HOMA-IR increased at 1.0, 5.0 and 10.0 mg/kg versus vehicle; lower doses were not marked significant in Table 1. Fasting glucose did not change significantly.[2]
Single-dose iloperidone versus vehicle
Model: Adult female Sprague-Dawley rats, 250–275 g; Figure 3A reports n=8–10 per group for the IGTT design.
Reported limits: Per-dose exact n and reagent salt form/lot were not provided in the selected source locations. Figure 3A gives only the group-size range.
Methods and source locations

Compound reported in the paper: Iloperidone; Compound label in the paper: Iloperidone

Acute rat results with the reported reagent; no Adooq lot validation or salt conversion.

Table 1, iloperidone rows and footnote; Results: IGTT; Materials and Methods: agents, IGTT chronology, insulin ELISA, HOMA-IR and statistics; Figure 3A caption

Fasting glucose at 30 min, before glucose challenge: Blood glucose measurement; no significant fasting-glucose effect reported. — Table 1, iloperidone G0 row and footnote; Results IGTT

Fasting plasma insulin at 30 min, before glucose challenge: Rat insulin ELISA, duplicate sample analysis; biological group means are distinct from duplicate assay wells. — Table 1, iloperidone I0 row and footnote; Plasma Insulin Measurement by ELISA

Fasting HOMA-IR at 30 min, before glucose challenge: HOMA-IR = fasting insulin × fasting glucose / 22.5, as specified by the authors; surrogate index, not clamp-derived insulin sensitivity. — Table 1, iloperidone HOMA-IR row and footnote; Insulin Resistance methods

Single-dose iloperidone versus vehicle · Table 1, iloperidone rows and footnote; Results: IGTT; Materials and Methods: agents, IGTT chronology, insulin ELISA, HOMA-IR and statistics; Figure 3A caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 133454-47-4
Formula C24H27FN2O4
Molecular Weight 426.5
Synonyms Fanapt; Fanapta; Zomaril
SMILES
CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 26 mg/mL (60.96 mM)
Water Insoluble
Ethanol 4 mg/mL (9.37 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1.5 mg/mL
Vehicle
2% DMSO+40% PEG 300+dd H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Iloperidone Research References

  1. [1] Janicot R, Maziarz M, Park JC, et al. Direct interrogation of context-dependent GPCR activity with a universal biosensor platform. Cell (2024). PMID: 38412860 DOI: 10.1016/j.cell.2024.01.028 Source material
  2. [2] Boyda HN, Procyshyn RM, Pang CC, et al. Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS One (2013). PMID: 23326434 DOI: 10.1371/journal.pone.0053459 Source material

Added to your cart

View Cart Checkout
Loading...